Analysis of the methods for projection of spaces for good manufacturing practice by Panovski-Nikoljski, Elena et al.
  
_______________________________________________________________________________________________________________________________ 
SEE J Archit Des. 2019 Dec 29; 10042:1-6.                                                                                                                                                                                       1 
 
ID Design Press 2012/DOOEL Skopje, Republic of Macedonia 
South East European Journal of Architecture and Design. 
Volume 2019; Article ID 10042, 6 pages 
https://doi.org/10.3889/seejad.2019.10042 
eISSN: 1857-9353 
Interior Design 
 
 
  
 
Analysis of the methods for projection of spaces for good 
manufacturing practice  
 
Elena Panovski-Nikoljski1, Aleksandar Petanovski2, Ivo Spiroski3* 
 
1Faculty of Design and Technology of furniture and interior, Ss Cyril and Methodius University of Skopje, Skopje, Republic of 
Macedonia; 2Faculty of Architecture, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia; 3ID Design 
2012/DOOEL Skopje, Skopje, Republic of Macedonia 
 
Citation: Panovski-Nikoljski E, Petanovski A, Spiroski I. 
Analysis of Methods during projection of facilities of good 
manufacturing practice and human biobank. SEE J Archit 
Des. SEE J Archit Des. 2019 Dec 29; 10042:1-6. 
https://doi.org/10.3889/seejad.2019.10042 
Keywords: Heterogenous concepts of projecting; Bank for 
stem cells; Good manufacturing praxis of biobank; Human 
biobank 
*Correspondence: Ivo Spiroski. ID Design 2012/DOOEL 
Skopje, Skopje, Republic of Macedonia. E-mail: 
ispiroski@id-press.eu  
Received: 01-Oct-2019; Revised: 05-Nov-2019; 
Accepted: 07-Nov-2019; Online first: 29-Dec-2019 
Copyright: © 2019 Elena Panovski-Nikoljski, Aleksandar 
Petanovski, Ivo Spiroski. This is an open-access article 
distributed under the terms of the Creative Commons 
Attribution-NonCommercial 4.0 International License (CC 
BY-NC 4.0). 
Funding: This research did not receive any financial 
support. 
Competing Interests: The authors have declared that no 
competing interests exist. 
 
 
 
 
 
 
Abstract 
BACKGROUND: In this Paper we will present the evolution of the best practice for biobanks, the technical and 
medical standards for collecting, processing and storing, as well as the socio-economic standards for biobank 
management.  
AIM: The aim of this Thesis is to analyse and to present the methods for projection of spaces for good manufacturing 
practice.  
METHODS: The European Union has adopted guidelines for good manufacturing practice which define the   
requirements for manufacturing of sterile products. In the following text we will describe the details for determining 
microbiological cleanliness and cleanliness of the particles in the air, on the surfaces, etc. 
RESULTS: The length of time between the collecting of blood or tissues could affect the final result. The preparation 
of sterile products requires special conditions, in order the risk of microbiological contamination and certain 
pyrogenic contaminations to be minimized. We make difference between four levels of guidelines for good 
manufacturing practice, which in this Paper are taken from the practice of the European Union. Level A is local zone 
with high-risk procedures, e.g. filling, closing of bottles, opening of ampoules and bottles and making septic 
connections. Level B is aseptic preparation and filling of the samples. Level C and D are the clean spaces for less 
critical procedures for preparation of sterile products.  
CONCLUSION: Technical standards, medical standards, socio-economic standards for biobank management, 
informatics practices for biobanks, economic recommendations for biobanks have been established, as well as a 
quality of biobanks has been provided.  
 
 
 
 
Introduction 
 
Every year millions of biological samples are 
collected for different purposes, including main 
scientific investigations, clinical studies and 
epidemiological studies [1]. The biological samples are 
stored in biobanks, which could be also called biostores 
(biorepositories), resources for biological samples or 
centres for biological samples, which are used for 
further analyses. In the clinical laboratory the storing of 
blood and urine from patients is base for a number of 
examinations and analyses [2]. For making diagnosis, 
as well as for scientific investigations, are collected 
frozen tissues or formalin fixed tissues in clinical 
conditions [3]. Many years ago, the standard operative 
procedures, the reference standards and the quality 
control were the main requirements for the clinical 
laboratories. For clinical investigations were 
determined precise rules, whereas for the biological 
samples collected for scientific investigations they were 
not so precise. 
The first banks for stem cells and the most 
frequent in the world are the banks for stem cells from 
the umbilical cord. In the world have been developed 
banks for stem cells for family use and public available 
banks for stem cells. 
The banks for stem cells for family use are 
private banks, where one family is storing blood from 
the umbilical cord or isolated stem cells, which could be 
potentially used for some of the close members of the 
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family.  
 
Figure 1: Donating blood from the umbilical cord in public and private 
bank 
 
Public available banks are funded by state 
institutions or by foundations, where married couples 
by signed consent are donating the blood from the 
umbilical cord, from which the stem cells are isolated 
and stored and they are used for any patient, if this 
patient is genetically identical. 
In rare cases the samples from the stored stem 
cells of the family from the family banks for stem cells 
later could be donated to the public banks for stem cells 
and to be used for patients beyond their family. 
Generally this is done with adequate material 
compensation. Because the family is paying for the 
storing of the stem cells and in the public banks the 
patients are not paying for it, but the costs are borne by 
the country. 
In the recent years a number of organisations 
have evolved and published numerous best practices 
which regulate the principles for storing biological 
samples [4]. These documents cover the technical 
aspects of the biological samples, as collecting, 
processing, storing, providing quality, information 
systems for data collection, as well as ethical and 
regulatory issues, e.g. the informed consent, the 
privacy of the patients and the intellectual property. 
 
 
Results 
 
Technical standards 
The technical best practices include 
recommendations for “the bases” of the biobanks: 
collecting, processing, storing and distribution of 
biological samples, as well as the relevant data from 
the collections and its management. Recently, a new 
field in the science for biological samples has been 
presented, which tries to develop the best practices 
based on evidences and standard operative 
procedures [5]. Since the investigation of biological 
samples has been developed as a specific field, 
everything became more visible within the 
development of the best practices, based on the 
evidences from the literature. For example, evidences 
have been collected that the length of the time between 
the collection of blood or tissues could affect the final 
result [6]. Multiple defrosting and freezing of the blood 
samples, could also negatively affect on certain 
analytical procedures, although for nucleic acids, some 
hormones and microelements, these effects are 
minimal [7]. 
 
Medical standards for collecting, 
processing and storing 
Examples of variables which should be taken 
into consideration: 
- collecting blood - test tubes for collecting 
which contain etylenediaminetetraacetic acid (EDTA) 
or heparin, may affect the analysis [8]. 
 
Figure 2: Succession of procedures for taking blood from the 
umbilical cord 
 
- storing - for long-term storing of live cells in 
liquid nitrogen, crucial is the temperature. Other 
samples, as for example DNA or plasma, in most cases 
are instable if they are stored at -80°С in freezers or at 
higher temperatures [9]. 
- processing – the duration of fixing with 
formalin could affect the later analyses [10]. 
These and other significant recommendations 
are included in all documents for best practice of 
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biological samples. Most general recommendations 
are given in the documents of the International Society 
for Biological and Environmental Repositories (ISBER) 
[11] and taken from the practices of the Nacional 
Cancer Institute (NCI) [12]. Subsequently, the best 
practices should be consulted by the biobanks located 
in different places in the world, where the 
recommendations could be adjusted for the local needs 
and use [13]. 
 
Socio – economic standards for biobanks 
management 
Smaller biobanks, which are part of greater 
programms or institutions should not have managing 
structure, except if they are existing as greater 
organisations. Although, the managing and the 
operative structures are important for great academic, 
governmental and commercial biobanks. These 
practices usually include managing and plan for the 
employees, roles and responsibilities of all employees, 
external committees that give advices for the scientific 
initiatives and apply the policy of biological samples, 
business planning and covering of costs, planning and 
using, as well as equipment and materials, necessery 
for the work [14]. 
 
Informatics practices for biobanks 
The information science in biobanks is 
covering some critical areas: following of biological 
samples, collecting of samples (clinical, quality of 
samples, demography) and identification of elements 
needed for each investigation, data security and 
privacy protection, as well as interoperability of the 
systems [15]. Interoperability of information science of 
the biobanks enables data exchange within biobanks 
which are functioning as part of one network. Some 
other informatics problems for biobanks, are:  
- Which type of finding, following, collecting of 
data and analysis of data would be necessary? 
- If these needs could be fulfilled by the existent 
institutional systems or an introduction of new 
commercial systems would be needed?  
- If the collecting and the exchange of systems 
would be compatible in the biobank? Would it be 
necessary a new web interface for data collection to be 
created? 
The best practices for informatics in biobanks 
include recommendations for resolving these issues, 
when new biobank or development of network of 
biobanks is planned to be established. 
 
Economic recommendations for biobanks 
A lot of biobanks are developed with a little 
knowledge of the good business practices or through 
covering of costs by the institutions and scientists that 
are using the biological samples. Though, the 
economic recommendations began to be included in 
the best practices, including those of NCI [16], because 
substantial financial means are needed for collecting, 
processing and storing of large collections. These 
recommendations include adjusting the standard 
business practices, in order all costs connected to 
establishing and maintaining the biobanks, to be 
understood. These costs include employees, 
equipment and its maintenance, maintaining quality 
and information science for data collection. When we 
will understand well all these costs, the fully or partial 
covering of the costs could provide long term 
sustainability of biobanks and discourage the requests 
for huge number of samples [17]. For a lot of 
examinations is the money refund not adequate, 
because the price for collecting biological samples is 
included in the projects or in the contracts for 
supporting the examination. 
 
Providing quality of the spaces for good 
manufacturing practice  
One of the main issues connected to the best 
practice of biobanks is the plan for quality 
management, which consists of providing quality and 
quality control. The definitions for providing quality and 
control of quality of biobanks are similar to that of the 
laboratories and other organisations which have that 
kind of plans for following the activities [18]. As shown 
in the best practice of NCI, an effective system for 
quality management requires: 
- Maintenance of the equipment and protocols 
for repair and following; 
- Training and observing the work 
recommendations by the employees; 
- Plan for data management; 
- Formal following procedure; 
- Development and observing the standard 
operative processes (SOP); 
 
Special nature of biobanks requires 
instructions for standard operative procedures, which 
describe the following policies and procedures:  
1. handling of biological samples; 
2. laboratory procedures; 
3. protocols for sending and receiving of 
materials; 
4. contracts for transfer; 
5. system for records management; 
6. security of the building, the personnel and 
the biological samples;  
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7. waste safety and waste disposal; 
8. procedures for reviewing documents and 
reports for injuries of employees and exposures to 
danger;  
9. maintaining the equipment, repair and 
marking the calibrations; 
 
These policies and procedures should be used 
for writing a plan for quality control, which would help 
the external controllers of biobanks and their 
managerial structures to examine the compliance with 
SOP [19]. 
 
Specifics for projection of spaces for good 
manufacturing practice 
Use of clean room [20] 
There are many standards for using a clean 
room, depending on its use. Generally, clean rooms are 
constructed for manufacturing of processors in the 
industrial informatics, manufacturing of sterile 
pharmaceutical preparations, for preparing of stem 
cells, as well as for other similar procedures. For all the 
types of clean rooms are prescribed standards for their 
construction, equipping and functioning, and in this 
case will be used the European recommendations for 
good manufacturing practice of medical products for 
human and animal use [21]. 
Principle: The preparation of sterile products 
requires special conditions in order the risk of 
microbiological contamination and certain pirogenic 
contaminations to be minimized. It depends the most 
from the experience, training and the conduct of the 
personnel included. Quality assurance is especially 
important and this type of production must strictly follow 
the carefully determined and confirmed methods for 
preparation and procedure. The final sterilization or the 
other aspects of quality must be part of each final or 
complete product.  
General remarks: 1. Creation of sterile 
products should be done in rooms with clean air, where 
the air from the personnel, the equipment and the 
materials is strictly controlled. Clean rooms should be 
maintained with certain cleanliness and be provided 
with air, which passes through filters with certain 
efficacy; 2. Various procedures for preparation of the 
products, as well as the filling should be done in special 
parts of the clean area. The creation of products is 
divided into two categories – first, the category where 
the product is terminally sterilized and second, the 
category where the product is processed aseptically, 
for some or for all rates; and 3. Clean rooms for 
production of sterile products are classified according 
to the characteristics of the environment needed. Each 
production operation requires relevant level of 
cleanliness of the environment in operative condition, 
in order the risk of particles or microbial contamination 
of the product or the created materials to be minimized.  
For „operative“ conditions to be achieved, 
these areas should be designed for achieving certain 
level of air cleanliness „at standstill“. „Standstill“ is 
condition when the installations are installed and are 
completely functioning with the equipment, but the 
personnel is not present. „Operative“ condition is 
condition when the installations are functioning in the 
defined operative way with certain number of working 
personnel.  
The conditions „at standstill“ and „operativity“ 
sholud be defined for each clean room and to 
corespond to the conditions for clean room [22]: 
a) „at standstill“ or „inactivity“: when the objects 
and systems are fully installed and are working, but in 
absence of operators;  
b) „operative“ or „activity“: when the objects 
and systems are in working mode, with presence of 
operators.  
For production of sterile medical products, we 
make a difference of 4 levels (Table 1). 
Table 1: Number of maximum allowable particles in m3 in the 
rooms at standstill and during operation, for preparation of 
sterile solutions  
 Number of maximum allowable particles in m3
 
equal to or bigger than the 
tabular number  
 At standstill During operation 
Level 0,5 µm 5,0 µm 0,5 µm 5,0 µm 
А 3 520 20 3 520 20 
B 3 520 29 352 000 2 900 
C 352 000 2 900 3 520 000 29 000 
D 3 520 000 29 000 Nondefined Nondefined 
 
 
Level А: local zone with high risk procedures, 
e.g. zones for filling, closing of bottles, opening of 
ampoules and bottles, making aseptic connections. 
These ingredients are provided by equipment with 
laminar air flow. The systems for laminar air flow should 
provide homogeneous speed of the air, ranging from 
0,36 to 0,54 m/s (recommended values) in the working 
area, from the rooms with open working space. 
Maintaining of laminarity should be shown and 
validated. One direction air flow and lower speeds 
could be used in closed isolators and boxes, with hand 
gloves. 
Level B: for aseptic preparation and filling an 
environment with Level A is needed.  
Level C and D: clean rooms for conducting 
less critical procedures during preparation of sterile 
products.  
Clean rooms and the equipment for clean air 
may be classified according to the standard EN ISO 
14644-1. The number of maximum allowable particles 
in the air is given in Table 1. 
Classification of clean rooms 
Clean rooms and the equipment for clean air 
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should be classified according to EN ISO 14644-1 [23]. 
The classification should be clearly differed from the 
conditions for following the operative process. The 
maximum allowable concentration of air particles for 
each level should be given in Table 1. 
Table 1: Number of maximum allowable particles in m3 in the 
spaces at standstill and during operation, for preparation of 
sterile solutions  
 
Number of maximum allowable particles in m3
 
equal to or bigger than 
the tabular number  
At standstill During operation 
Level 0,5 µm 5,0 µm 0,5 µm 5,0 µm 
А 3 520 20 3 520 20 
B 3 520 29 352 000 2 900 
C 352 000 2 900 3 520 000 29 000 
D 3 520 000 29 000 Nondefined Nondefined 
 
For classification of the zones from Level A at 
least one m3 of air for each location is needed. For 
Level A of the classification of air particles the standard 
ISO 4.8 is determining a limit of the particles equal or 
bigger than 5,0 µm. For Level B „at standstill“, the 
classification of air particles is ISO 5 for both 
designated sizes of the particles. For Level C „at 
standstill and during operation“, the classification of air 
particles is ISO 7 and ISO 8. For the level D „at 
standstill“ the classification of air particles is ISO 8. For 
classification according to EN ISO 14644-1, the 
methodology is defining minimal number for each 
location and size according to the limit of the class of 
the largest particles and the method for determining the 
collection of data. A mobile particle counters with short 
test tubes for collecting should be used, because of the 
relatively high precipitation level i.e. „sedimentation“ of 
the particles, equal of bigger than 5,0 µm, which 
happens in the remote systems for taking samples with 
large length of the test tube. An isokinetic sample 
heads, that use system of one directed passing air, 
should be used. The classification „during operation“ 
may be shown during normal functioning, simulated 
functioning or during filling of medium, as the worst 
simulation needed for this standard. EN/ISO 14644-2 
gives information for testing and shows continued 
compliance with the classification of cleanliness.  
 
 
Conclusions 
 
Based on the analysis of methods for 
projection of the spaces for good manufacturing 
practice we could come to the following conclusions: 
Analysing the conditions in the developed 
world it is determined that there are and are developed 
banks for stem cells for family use and public available 
banks for stem cells. The banks for stem cells for family 
use are private banks, where the family is storing blood 
from the umbilical cord or isolated stem cells, which 
could potentially be used for one of the close members 
of the family. Public available banks are funded by state 
institutions or foundations, where married couples by 
signed consent are donating blood from the umbilical 
cord, from which stem cells are isolated and stored and 
subsequently used for any person, if this person is 
genetically identical. 
The results of this Paper for analysis of the 
methods for projection of the spaces for good 
manufacturing practice would contribute for following 
the medical standards for collecting, processing and 
storing of biological samples, on behalf of the 
healthcare. 
The conditions for production of sterile 
products that define the instructions for good 
manufacturing practice in this Paper are taken from the 
European practice. We make a difference between four 
levels of instructions for good manufacturing practice, 
which in this Paper is taken from the European 
practice. Level A is local zone with high-risk 
procedures, e.g. filling, closing of bottles, opening of 
ampoules and bottles and making septic connections. 
Level B is aseptic preparation and filling of the samples. 
Level C and D are the clean spaces for less critical 
procedures for preparation of sterile products. 
Technical standards, medical standards, 
socio-economic standards for biobank management, 
informatics practices for biobanks, economic 
recommendations for biobanks have been established, 
as well as the quality of biobanks has been provided. 
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